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Background: Recent epidemiologic studies have shown that the use of psychotropics is associated with
many symptoms and may result in dependence and tolerance among elderly individuals. The aim of this
study was to describe the symptoms related to withdrawal or dose reduction of long-term benzodiaz-
epine (BZD) or BZD-related drugs (RDs) use and to compare them with nonuse of these drugs in
community-dwelling individuals aged 65 and older.
Methods: The study was a post hoc analysis embedded in a 12-month randomized, controlled fall-
prevention trial that included withdrawal of BZDs and RDs. The participants (n ¼ 248) in the inter-
vention group were divided into the following four groups according to their use of BZDs/RDs at baseline
and follow-up: (1) withdrawal (WG), (2) reduction (RG), (3) unchanged (UG), and (4) nonusers (NUG).
Differences in symptom changes were compared between and within these four groups.
Results: Using BZD/RD was associated with numerous symptoms at baseline and during the intervention.
At follow-up, those symptoms reduced signiﬁcantly among all participants. However, there were no
signiﬁcant differences between the groups in the changes of symptoms during the follow-up. Self-
perceived health improved in only NUG (p < 0.001), but not in the other groups (WG, RG, and UG).
Conclusion: Withdrawal or reduction of BZD/RD produced positive effects on physical, psychological, or
cognitive symptoms among all participants, but no differences between the groups were detected. We
recommend that clinical goals should be carefully assessed against the risks of long-term BZD/RD use,
and that withdrawal interventions should be initiated for community-dwelling users aged 65 and older,
especially those long-term users who may already be experiencing adverse drug effects.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Benzodiazepines and BZD-related drugs (BZDs/RDs) are widely
prescribed1 and long-term BZD/RD use is common. However, psy-
chotropics tend to be overprescribed and overused in patients agedre that they have no conﬂicts
dicine, University of Turku,
tric Emergency & Critical Care Me65 years and older, the age group most vulnerable to their adverse
effects. Use of psychotropics is common among patients with
memory disturbances or dementia2. In Europe, the prevalence of
BZD/RD use is about 2e3% in the general population, whereas its
prevalence in the aged individuals varies between 10% and 42%
worldwide3.
Primary insomnia and anxiety are the most common clinical
indications for prescribing BZD or RD; however, this is associated
with certain risks. Cross-sectional and longitudinal studies show
that BZD/RD use among the elderly population is associated with
sedation, sleep disorders, depression, psychomotor and cognitivedicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Flowchart for the identiﬁcation of participants from the longitudinal fall-
prevention trial. BZDs ¼ benzodiazepine; RDs ¼ BZD-related drugs.
Association Between BZD/RD Use and Various Symptoms 35impairments, motor vehicle accidents, and increased risk of falls
and fall-related injuries4e6.
Long-term BZD/RD use may result in dependence and tolerance.
These risks are especially high among individuals aged 85 years or
over, and among those with cognitive impairment, poor health,
mental disorders, previous use of BZDs/RDs, concomitant antide-
pressant use, multiple drug use, and multiple chronic and psychi-
atric diseases6.
In this study, an intervention implemented by our research team
included a one-time individual counseling session followed by a
group lecture about the risks of adverse effects from BZD/RD use,
and recommendations to reduce or stop long-term BZD/RD use7.
Using the trial data, we carried out a post hoc analysis and assessed
whether withdrawal or reduction of BZDs/RDs would be associated
with changes in physical, psychological, or cognitive abilities in
individuals aged 65 years and older.
2. Materials and methods
2.1. Participants and study design
Participants (n ¼ 591) were 65 years or older in a multifactorial,
randomized, controlled fall-prevention trial lasting 12 months
(registered in ClinicalTrials.gov, ID ¼ NCT00247546). The trial has
been previously described in more detail8. The number of regular
users of BZDs/RDs decreased signiﬁcantly by 35% in the interven-
tion group and correspondingly increased by 4% in the controls7.
Participants (n ¼ 248) belonging to the intervention group and
participating in follow-up examinations formed the study group for
the present study's longitudinal analyses. The use of BZD/RD was
not randomized (Fig. 1). Ethics approval was obtained from the
Ethics Committee of Satakunta Hospital District and written
informed consent from the participants was also obtained.
For the longitudinal analyses, participants were divided into
four groups according to their usage of BZDs/RDs at the baseline
and after the 12-month intervention: (1) those participants who
totally stopped BZD/RD used formed the withdrawal group (WG);
(2) those who reduced BZD/RD use formed the reduction group
(RG); (3) those who did not change their BZD/RD use formed the
unchanged group (UG); and (4) those not using BZD/RD at baseline
and after 12 months formed the nonuser group (NUG). In-
terventions (geriatric assessment, guidance, lectures, and psycho-
social support) performed in all groups were identical.
At the baseline and after the 12-month intervention, a senior
clinical geriatrician (M.S.) collected drug-utilization data (1) by
interviewing the participants, and (2) from the medical records. All
participants were asked to take their prescriptions and pillboxes of
regularly or irregularly used drugs to the interviews. For those who
had higher Geriatric Depression Scale (GDS) scores, the geriatrician
prescribed antidepressant treatment with caution. Antidepressant
treatment was started only if the participant was diagnosed to
suffer from major depression. Drugs were coded using a Finnish
translation of the Anatomical Therapeutic Chemical (ATC) Classiﬁ-
cation System9. BZDs and RDs consisted of medications included in
the following ATC codes: N05BA, N05CD, N05CF, A03CA, N03AE01,
R06AE53, and N06CA01. Participants received individually
designed withdrawal program by the geriatrician. The program has
been previously described in more detail7.
The participants' physical symptoms were measured at baseline
and during the follow-up examination. These used structured
questions about palpitation, hand tremor, incontinence, dizziness
while walking and dizziness while arising, tendency to fall, and
heavy perspiration without physical exercise. For every symptom,
participants were asked: “Have you had the following symptoms
during the most recent 14 days, and if so, how frequently?” Theoccurrence and frequency of these symptoms were rated on scales
covering the following four frequencies: 1 ¼ not at all; 2 ¼ every
now and then; 3 ¼ almost daily; and 4 ¼ daily. Psychological and
cognitive symptoms were ascertained from questions about
insomnia, lack of conﬁdence while walking, unwillingness and
powerlessness, tiredness and weakness, anxiety, memory loss, and
global cognitive abilities. For every symptom, participants were
asked: “Have you had the following symptoms during the most
recent 14 days, and if so, how frequently?” For statistical analyses,
answers in symptom items were combined into two categories
(yes/no), because of the small numbers of observations in some of
the categories.
S. Vaapio et al.36In addition, questions were asked concerning quality of life
satisfaction, loneliness, and self-perceived health. These were
measured with ﬁve-point scales. Life satisfaction: 1 ¼ very unsat-
isﬁed; 2 ¼ unsatisﬁed; 3 ¼ neither satisﬁed nor unsatisﬁed;
4 ¼ satisﬁed; and 5 ¼ very satisﬁed; Loneliness: 1 ¼ never;
2¼ seldom; 3¼ every now and then; 4¼ often; and 5¼ constantly;
Self-perceived health: 1 ¼ very poor; 2 ¼ poor; 3 ¼ neither poor nor
good; 4 ¼ good; and 5 ¼ very good. In the statistical analyses, self-
perceived health was combined into three categories (1 ¼ good;
2 ¼ moderate; and 3 ¼ poor), because of the small numbers of
observations in some of the categories.
Global cognitive abilities were measured with the Mini-Mental
State Examination (MMSE)10. Scores and subcomponents were
used to derive categories and additional clinical information on
cognitive impairment: 1 ¼ moderate (score ¼ 17e24); 2 ¼ normal
(score ¼ 25e30). The MMSE includes the serial sevens test
(range ¼ 0e5) and the recall test (range ¼ 0e3). The number ofTable 1
Baseline characteristics of participants in the intervention group by changes in BZD/RD u
Users of BZDs/RDs at ba
Withdrawal
group (n ¼ 31)
Reduction
group (n ¼ 2
n (%) n (%)
Sex
Male 3 (10) 1 (4)
Female 28 (90) 24 (96)
Age
65e74 (y) 17 (55) 18 (72)
75 (y) 14 (45) 7 (28)
Marital status
Single 2 (6) 1 (4)
Married or cohabiting 17 (55) 12 (48)
Widowed, divorced, or legally separated 12 (39) 12 (48)
Living circumstances
Alone 13 (42) 13 (52)
With a spouse or other person(s) 18 (58) 12 (48)
Living place
Home 29 (94) 22 (88)
Sheltered housing 2 (6) 3 (12)
Number of prescribed medications
<4 13 (42) 8 (32)
4 18 (58) 17 (68)
Diseases
Cardiovascular diseases 21 (68) 17 (68)
Musculoskeletal disorders 19 (61) 17 (68)
Pulmonary diseases 5 (16) 6 (24)
Malignancies 2 (6) 2 (8)
Psychiatric disease 5 (16) 4 (16)
Neurological disease 5 (16) 6 (24)
MMSE (range, 0e30)
25e30 28 (90) 24 (96)
17e24 3 (10) 1 (4)
GDS (range, 0e30)
0e10 28 (93) 18 (75)
11e30 2 (7) 6 (25)
BBS (range, 0e56)
45e56 2 (6) 2 (8)
0e44 29 (94) 23 (92)
Agea (y) 74.0 (68.0e77.0) 72.0 (68.0e7
Number of prescribed medicationsa
Regularly 4.0 (2.0e6.0) 5.0 (2.0e7.0
Irregularly 2.0 (1.0e4.0) 2.0 (1.0e4.0
Number of diseasesa 4.0 (3.0e5.0) 4.0 (2.0e6.0
MMSEa 28.0 (27.0e29.0) 28.0 (26.0e2
GDSa 4.5 (3.0e7.0) 4.5 (3.0e10
BBSa 54.0 (50.0e55.0) 53.0 (48.0e5
* Statistical signiﬁcance for the difference between the groups (WG, RG, UG, and NUG).
a Median (lower quartileeupper quartile).
BBS ¼ Berg Balance Scale; BZDs/RDs ¼ benzodiazepines or related drugs; GDS ¼ Geriatrdepressive symptoms was measured with the GDS-3011. It is cate-
gorized as follows: 1 ¼ a small number of depressive symptoms
(score ¼ 0e10), or 2 ¼ a high number of depressive symptoms
(score ¼ 11e30). The Berg Balance Scale12 was used as a measure of
functional balance: 1 ¼ decreased (score ¼ 0e44); 2 ¼ good
(score ¼ 45e56).2.2. Data analyses
Data were analyzed on an intention-to-treat basis13. The dif-
ferences in categorical background variables between users and
nonusers of BZDs/RDs and among the four groups (WG, RG, UG, and
NUG) were analyzed using Chi-square test or Fisher exact test. The
ManneWhitney U test and the KruskaleWallis test were used to
test the differences in continuous background variables between
the groups.se during the intervention.
Intervention group (n ¼ 248)
seline (n ¼ 91) Nonusers of BZDs/RDs at baseline p*
5)
Unchanged
group (n ¼ 35)
Nonusers
group (n ¼ 157)
n (%) n (%)
3 (9) 27 (17) 0.186
32 (91) 130 (83)
18 (51) 109 (69) 0.105
17 (49) 48 (31)
1 (3) 12 (8) 0.416
11 (31) 65 (41)
23 (66) 80 (51)
23 (66) 89 (57) 0.261
12 (34) 68 (43)
34 (97) 155 (99) 0.028
1 (3) 2 (1)
12 (34) 88 (56) 0.022
23 (66) 69 (44)
28 (80) 106 (68) 0.537
25 (71) 105 (67) 0.859
5 (14) 27 (17) 0.789
2 (6) 7 (4) 0.718
6 (17) 1 (1) <0.001
5 (14) 24 (15) 0.708
29 (83) 142 (92) 0.318
6 (17) 13 (8)
24 (71) 137 (89) 0.011
10 (29) 17 (11)
5 (14) 15 (10) 0.729
30 (86) 142 (90)
6.0) 74.0 (70.0e77.0) 72.0 (69.0e75.0) 0.631
) 5.0 (3.0e6.0) 3.0 (1.0e5.0) 0.002
) 2.0 (1.0e3.0) 1.0 (0e2.0) <0.001
) 4.0 (3.0e6.0) 3.0 (2.0e4.0) 0.008
9.0) 27.0 (26.0e29.0) 28.0 (27.0e29.0) 0.491
.5) 5.5 (2.0e12.0) 3.0 (1.0e6.0) 0.011
5.0) 53.0 (48.0e55.0) 53.0 (50.0e55.0) 0.696
ic Depression Scale; MMSE ¼ Mini-Mental State Examination.
Association Between BZD/RD Use and Various Symptoms 37Baseline differences between the groups were assessed using
logistic regression. During follow-up, the changes in GDS-30 and
MMSE sum scores, serial sevens, and recall tests within the groups
and the changes between the groups were analyzed using analysis
of covariance. The changes in symptoms within the groups and the
differences in changes between the groups (interaction effect
group  time) were analyzed by logistic regression analyses using
generalized estimation equations to account for correlations be-
tween repeated measurements14. An exchangeable correlation
structure was used in the analyses.
The results of logistic models were quantiﬁed by calculating
odds ratios (ORs) for dichotomous outcome variables and cumu-
lative ORs (CORs) for ordinal outcome variables, including their 95%
conﬁdence intervals (95% CI). The p values of 0.05 and less were
considered statistically signiﬁcant. All p values were calculated
with two-sided tests, and no adjustments were made for multi-
plicity. Analyses were performed with the SAS System for Win-
dows, version 9.1 (SAS Institute Inc., Cary, NC, USA).3. Results
3.1. Baseline characteristics and symptoms in the intervention
group
The four groups (WG, RG, UG, and NUG) differed signiﬁcantly
from each other in some baseline characteristics (Table 1). Psychi-
atric diagnoses were more common in WG, RG, and UG than in
NUG, and the participants in these groups had more diseases and
depressive symptoms and used more prescribed medications than
participants in NUG. At the baseline, insomnia was more common
in WG than in NUG (OR ¼ 5.9; 95% CI ¼ 1.8e19.2, p ¼ 0.003).
Anxiety was less common (OR ¼ 0.3, 95% CI ¼ 0.1e1.0, p ¼ 0.049),
but loneliness was more common (OR ¼ 3.1, 95% CI ¼ 1.0e9.2,
p ¼ 0.041) in WG than in UG.Table 2
Symptoms in the intervention group at baseline and after the 12-month intervention by
Physical symptoms Baseline n (%) F
Palpitation 107 (47)
Tremor of hands 66 (29)
Incontinence 90 (40)
Dizziness while walking 114 (49)
Dizziness while arising 127 (55)
Tendency to fall 64 (28)
Heavy perspiration without physical exercise 93 (39)
Psychological/cognitive symptoms
Insomnia 167 (68)
Lack of conﬁdence with walking 106 (46) 1
Unwillingness and powerlessness 116 (50)
Tiredness and weakness 133 (58)
Anxiety 61 (27)
Memory loss 146 (63) 1
Life satisfaction 58 (24)
Loneliness 147 (61) 1
Median (lower quartileeupper quartile)
MMSE 28.0 (27.0e29.0) 28.0 (27.0e29.0
Serial sevensb 5.0 (4.0e5.0) 5.0 (4.0e5.0)
Recallc 2.0 (1.0e3.0) 2.0 (2.0e3.0)
GDSd 4.0 (2.0e8.0) 2.0 (1.0e5.0)
BBS 53.0 (50.0e55.0) 54.0 (51.0e56.0
* Statistical signiﬁcance for the change between the baseline and the follow-up among a
a Adjusted for group, living place, prescribed medications (regularly and irregularly),
decrease in the symptoms. There were no differences in the changes of symptoms betw
b Serial sevens test of MMSE (range, 0e5).
c Recall test of MMSE (range, 0e3).
d Adjusted for group, living place, prescribed medications (regularly and irregularly),
BBS¼ Berg Balance Scale; BZDs/RDs¼ benzodiazepines or related drugs; CI¼ conﬁdence i
OR ¼ odds ratio.Participants who used BZDs/RDs regularly (15%) or irregularly
(29%) mostly did so to treat sleep disorders. Morewomen and older
persons used BZDs/RDs than men or the younger participants. The
most common drug was zopiclone and the others were temaze-
pam, zolpidem, and oxazepam. One third of the intervention group
withdrew from regular use and almost one third withdrew from
irregular use7.3.2. Changes in symptoms during the intervention
There were no differences in the changes of symptoms between
the groups. Therefore, symptoms were not analyzed separately
within the groups. The analyses were adjusted for group and con-
founding factors (living place, number of prescribed medications,
number of diseases, and a high number of depressive symptoms).
Those participated in the intervention had less palpitation, hand
tremors, dizziness while walking and arising, falling tendency, and
heavy perspiration without physical exercise at follow-up than at
baseline. Signiﬁcant changes were also detected in some psycho-
logical/cognitive symptoms. Insomnia, lack of conﬁdence with
walking, unwillingness and powerlessness, tiredness and weak-
ness, and anxiety decreased during follow-up (Table 2). These
symptoms were reduced among those who managed to withdraw
their BZDs/RDs or reduce their use during the intervention (data
not shown).
Self-perceived health improved in NUG (COR ¼ 2.5, 95% CI
1.6e2.8, p < 0.001). In WG, the change of self-perceived health was
not statistically signiﬁcant (COR ¼ 1.7, 95% CI ¼ 0.7e4.0, p ¼ 0.211),
which was also the case in RG (COR ¼ 0.9, 95% CI ¼ 0.3e2.3,
p ¼ 0.767) and in UG (COR ¼ 0.7, 95% CI ¼ 0.3e1.4, p ¼ 0.283;
Table 3).
A signiﬁcant difference in these changes in self-perceived health
was found between WG, RG, UG, and NUG (interaction effect
group  time, p < 0.001) after adjustment for confounding factors.changes in the participant's BZD/RD use during the intervention.
ollow-up n (%) Adjusteda OR for change (95% CI) p*
72 (32) 0.5 (0.4e0.7) <0.001
45 (20) 0.6 (0.4e0.8) <0.001
72 (32) 0.7 (0.5e0.9) 0.012
82 (36) 0.6 (0.4e0.7) <0.001
86 (37) 0.4 (0.3e0.6) <0.001
13 (6) 0.1 (0.1e0.3) <0.001
63 (27) 0.5 (0.4e0.7) <0.001
71 (31) 0.6 (0.4e0.8) <0.001
61 (70) 0.5 (0.4e0.7) <0.001
97 (42) 0.7 (0.5e1.0) 0.035
94 (41) 0.5 (0.3e0.6) <0.001
41 (18) 0.5 (0.4e0.8) 0.006
31 (57) 0.8 (0.5e1.1) 0.099
56 (23) 1.0 (0.7e1.6) 0.889
45 (60) 1.0 (0.7e1.3) 0.901
Adjusted mean difference (95% CI) p
) 0.23 (1.2 to 0.7) 0.638
0.17 (0.8 to 0.4) 0.575
0.03 (0.4 to 0.5) 0.869
0.12 (1.9 to 2.1) 0.908
) 1.2 (2.5 to 0.1) 0.074
ll participants.
number of diseases, and a high number of depressive symptoms; OR < 1 indicates
een the groups.
and number of diseases.
nterval; GDS¼ Geriatric Depression Scale; MMSE¼Mini-Mental State Examination;
Table 3
Self-perceived health in the intervention group at baseline and after the 12-month intervention by changes in BZD/RD use during the intervention within the groups.
Baseline Follow-up COR (95% CI) p*
Good Moderate Poor Good Moderate Poor
n (%) n (%) n (%) n (%) n (%) n (%)
WG 4 (13) 23 (74) 4 (13) 9 (29) 17 (55) 5 (6) 1.7 (0.7e4.0) 0.211
RG 5 (20) 18 (72) 2 (8) 7 (28) 14 (56) 4 (16) 0.9 (0.3e2.3) 0.767
UG 8 (24) 21 (62) 5 (15) 6 (18) 22 (65) 6 (18) 0.7 (0.3e1.4) 0.283
NUG 35 (23) 104 (68) 13 (9) 66 (43) 76 (50) 10 (7) 2.5 (1.6e2.8) <0.001
Signiﬁcant difference in the changes of the symptoms between the groups was found in self-perceived health (interaction effect group  time, p < 0.001).
* Statistical signiﬁcance for the change between the baseline and the follow-up within the groups.
BZDs/RDs ¼ benzodiazepines or related drugs; CI ¼ conﬁdence interval; COR ¼ cumulative odds ratio; NUG ¼ nonusers group (n ¼ 157); RG ¼ reduction group (n ¼ 25);
UG ¼ unchanged group (n ¼ 35); WG ¼ withdrawal group (n ¼ 31).
S. Vaapio et al.38The change in self-perceived health in NUG was signiﬁcantly
different than that for UG (interaction effect group  time,
p¼ 0.002). No other statistically signiﬁcant differences between the
groups were detected. In addition, WG and RGwere compared with
UG. There were no signiﬁcant differences between the user groups
WG and RG compared with UG during follow-up.
4. Discussion
The results showed self-perceived health improving signiﬁ-
cantly among those not using BZDs/RDs during the intervention
and slightly among individuals withdrawing or reducing BZD/RD
use. However, the study sample was quite small, and the use of
BZD/RD was not randomized; therefore, the tendency for improved
self-perceived health should be taken into consideration. Further
analyses of subpopulations (among those aged  75 or with a
higher risk of adverse effects of BZDs/RDs) were not possible due to
the small number of individuals in this study.
More than half of the participants were 65e74 years of age and
their health was quite good. In the younger aged participants, BZD/
RD use may be a smaller risk factor for adverse effects and events
than for those of more advanced age, more chronic diseases, and/or
poorer general health. The results might have been different if more
frail and older participants had been included, as the compensative
reserve capacity reduces and pharmacodynamics and pharmaco-
kinetics change with aging.
Our study was part of a randomized, controlled trial and based
on secondary analyses15. Many variables were measured using
standardized and internationally validated rating scales, though
some of the participants' symptoms, such as life satisfaction,
loneliness, and self-perceived health were assessed using Likert-
type scales. Answers to symptom-item questions were combined
into two or three categories, and those scales are not sensitive for
changes.
At baseline, women and persons living in sheltered housing
formed a greater proportion of the users, and they received more
medications, had more depressive symptoms and diagnoses. In
addition, their balance was worse and they were older. To control
for these confounders, we adjusted multivariable models. Even
after adjustments, more of the BZD/RD users suffered from
insomnia, indicating that long-term BZD/RD use does not
normalize the self-perceived quality of sleep16.
Withdrawers had fewer depressive symptoms and they had
been less anxious than nonwithdrawers at baseline. Differences in
these symptoms might explain why some participants could
withdraw while others could not. The intervention is based on the
participants' willingness to discontinue or reduce their BZD use17. It
may be that those who managed to discontinue their BZD use will
have a better perception of health than the others. This may also
inﬂuence the results on the reduced symptomatology.However, because of the retrospective categorization of WG, RG,
UG, and NUG, it is possible that those participants with the most
symptoms related to indications of (short term) BZDs/RDs were not
able to reduce their use of BZDs/RDs because of increased symp-
toms related to BZDs/RDs withdrawal18,19. Many participants'
opinion was that withdrawal or reduction of BZD/RD will cause
more problems than the use of the medication.17
Multiple physical, psychological, and cognitive symptoms were
reduced in the fall-prevention trial's intervention group. Because
the intervention consisted of evidence-based psychosocial support
and physical exercise components19, the results are consistent with
and extend related prior research and theory. These symptoms
were reduced among those who managed to withdraw their BZDs/
RDs or reduce their use during the intervention. After adjusting for
the confounders, only self-perceived health tended to improve in
the WG and in the group reducing their use of BZDs/RDs. However,
a signiﬁcant positive change occurred in BZDs/RD nonusers, indi-
cating that the tendency to improve in the WG and RG may not be
solely due to the withdrawal or reduction of these drugs. A holistic
intervention may have affected them at least partly.
There is a need for further education regarding psychotropics
use by primary-care physicians/family physicians4,20. To maximize
the beneﬁts and minimize the risks of psychotropic drug use in
older people20,21, clinicians should be aware of the prevalence,
dependence, and evidence of serious adverse effects from BZD/RD
use and the beneﬁts of withdrawal or dose reduction. It is recom-
mended that psychotropic drugs should be prescribed with
caution, balancing beneﬁts and risks. They should be used in small
doses and for short periods, assessing carefully and continuously
the indications for use and need for them. The indications for long-
term BZD or RD use should be carefully assessed, and withdrawal
interventions should be targeted to long-term users experiencing
adverse effects from these drugs.References
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